Prevention of progression of cognitive decline in the first-degree relatives of patients with Alzheimer’s disease

Selezneva N.D.; Roshchina I.F.; Korovaĭtseva G.I.; Gavrilova S.I.

doi:https://doi.org/10.17116/jnevro201811810130

Selezneva N.D.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Roshchina I.F.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Korovaĭtseva G.I.

Nauchnyĭ tsentr psikhicheskogo zdorovia RAMN, Moskva

Gavrilova S.I.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

SPIN RSCI: 6094-4303
Scopus AuthorID: 7004829216
ResearcherID: B-4548-2016
ORCID: 0000-0001-6683-0240

Prevention of progression of cognitive decline in the first-degree relatives of patients with Alzheimer’s disease

Authors:

Selezneva N.D., Roshchina I.F., Korovaĭtseva G.I., Gavrilova S.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10): 30‑36

DOI: 10.17116/jnevro201811810130

Read: 1398 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Selezneva ND, Roshchina IF, Korovaĭtseva GI, Gavrilova SI. Prevention of progression of cognitive decline in the first-degree relatives of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10):30‑36. (In Russ.)
https://doi.org/10.17116/jnevro201811810130

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16

Arterial hypertension is an oxidative stress, as a pathogenetic target for the treatment of chronic cerebrovascular insufficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):84-90

The experience of diagnosing Alzheimer’s disease based on the study of cerebrospinal fluid biomarkers. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):91-97

Neurobiological potential of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):7-12

Cognitive vascular disorders and morphometric parameters of the prefrontal, dorsolateral cortex and thalamus in post-stroke patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):91-95

Cerebrolysin and the optimal timing of anticoagulation resumption in stroke: combined post hoc survival analysis of the CEREHETIS trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):77-93

Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77

The study of the behavioral reactions and duration of ultrasonic vocalization in rats from females stressed during pregnancy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):117-123

Results of the All-Russian consensus conference on complications in bariatric surgery. Endoscopic Surgery. 2025;(1):15-24

Characteristics, treatment features and in-hospital mortality of patients with myocardial infarction over 75 years old in Russia according to the REGION-IM registry. Russian Cardiology Bulletin. 2025;(1):22-38

Abstract:

Objective. To evaluate the efficacy of course neurotrophic therapy with cerebrolysin in a group of first-degree relatives of Alzheimer's disease (AD) patients who had minimal cognitive dysfunction. Material and methods. Sixty-seven relatives (mean age 57.6±14.2 y.o.) received cerebrolysin in the dose of 20 ml/day in intravenous drips in 100 ml isotonic saline. The duration of treatment was 1 month. Results. The positive effect of course treatment on the CGI was established in 77.6% of the relatives. The scores on the MMSE and MoCA scales were significantly improved in the group with cognitive difficulties objectively confirmed by the clinical/neuropsychological examination (n=27) and in the group without cognitive difficulties (n=40). Conclusion. The positive effect of cerebrolysin on the cognitive status of the first-degree relatives of AD patients, regardless of their cognitive deficiency, was demonstrated.

Keywords:

Alzheimer’s disease

first-degree relatives

cognitive functions

treatment

cerebrolysin

Authors:

Selezneva N.D.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Roshchina I.F.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Korovaĭtseva G.I.

Nauchnyĭ tsentr psikhicheskogo zdorovia RAMN, Moskva

Gavrilova S.I.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

SPIN RSCI: 6094-4303
Scopus AuthorID: 7004829216
ResearcherID: B-4548-2016
ORCID: 0000-0001-6683-0240

Close metadata

References:

Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer’s & Dementia. 2013;9:1:63-75. https://doi.org/10.1016/j.jalz.2012.11.007
Ryazanskaya NN, Dvoryanchikov G, Grigorenko A, Rogaev E. Polimorfizm v 5’-oblasti presenilina 2 (PS2). V kn.: Bolezn’ Al’cgejmera i starenie. Materialy II Rossijskoj konferencii. Pod red. Gavrilovoj S.I. M. 1999. (In Russ.)
La Rue A, Matsuyama SS, McPherson S, Sherman J, Jarvik LF. Cognitive performance in relatives of patients with probable Alzheimer disease: an age at onset effect? J Clin Exp Neuropsychol. 1992;14:33-538. https://doi.org/10.1080/01688639208402842
Selkoe D.E. Biochemistry and Molecular Biology of Amyloid β‐Protein and the Mechanism of Alzheimer’s Disease. Chapter published 2008 in Handbook of Clinical Neurology. 2008;245-260. https://doi.org/10.1016/s0072-9752(07)01223-7
Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, Thomas-Anterion C, Michon A, Martin C, Charbonnier F, Raux G, Camuzat A, Penet C, Mesnage V, Clerget-Darpou F, Frebourg T. Early-onset autosomal dominant Alzheimer’ disease: prevalence, genetic geterogenety and mutation spectrum. Americal Journal of Human Genetics. 1999;65:664-670. https://doi.org/10.1086/302553
Breithner JCS. Clinical genetics and genetic counselling in Alzheimer’s disease. Annals of Internal Medicine. 1991;115:601-606. https://doi.org/10.7326/0003-4819-601
McGuffin P, Owen MJ, O’Donovan MC, Thapar A, Gottesman Gaskell. Seminars in Psychiatric Genetics. London: Gaskell; 1994. https://doi.org/10.1136/bmj.309.6957.818a
Jarvik LF, Brazer D. Children of Alzheimer parents: An Overview. J Geriatr Psychiatry Neurol. 2005;18:181-186. https://doi.org/10.1177/0891988705281859
Small GW, Okonek A, Mandelkern MA, La Rue A. Age-associated memory loss: initial neuropsychological and cerebral metabolic findings of a longitudinal study. Int Psychogeriatr. 1994;6:23-44. https://doi.org/10.1017/s1041610294001596
La Rue A, O’Hara R, Matsuyama SS, Jarvik LF. Cognitive changes in young-old adults: effect of family history of dementia. J Clin Exp Neuropsychol. 1995;17:65-70. https://doi.org/10.1080/13803399508406582
Caselli RJ, Reiman EM, Osborne D, Hentz JG, Baxter LC, Hernandez JL, Alexander GG. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology. 2004;62:1990-1995. https://doi.org/10.1212/01.wnl.0000129533.26544.bf
Levy JA, Bergeson J, Putnam K, Rosen V. Context-specific memory and apolipoprotein E (APOE) epsilon 4: cognitive evidence from the NIMH prospective study of risk for Alzheimer’s disease. J Int Neuropsychol Soc. 2004;10:362-370. https://doi.org/10.1017/s1355617704103044
Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer’s disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer’s Prevention. J Geriatr Psychiatry Neurol. 2005;18(4):245-249. https://doi.org/10.1177/0891988705281882
Selezneva ND, Roshchina IF, Gavrilova SI, Fedorova YaB, Gantman MV, Korovajceva GI, Kunizheva SS, Rogaev EI. Psihicheskie narusheniya kognitivnogo i nekognitivnogo spektra u rodstvennikov 1 stepeni rodstva pacientov s bolezn’yu Al’cgejmera. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2012;112(10):8-13. (In Russ.)
Gavrilova SI, Fedorova YaB, Kolyhalov IV, Odinak MM, Emelin AYu, Kashin AV, Selezneva ND, Kalyn YaB, Roshchina IF. Terapevticheskij potencial cerebrolizina v preventivnoj terapii bolezni Al’cgejmera. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2008;108(8):24-29. (In Russ.)
Gauthier S, Proano JV, Jia J, Froelich L, Vester J, Doppler E. Cerebrolysin in Mild-to-Moderate Alzheimer’s Disease: A Meta-Analysis of Randomized Controlled Clinical Trials. Dement Geriatr Cogn Disord. 2015;39:340-55. https://doi.org/10.1016/j.jalz.2014.05.1709
Gavrilova SI, Kolyhalov IV, Fyodorova YaB, Selezneva ND, Kalyn YaB, Roshchina IF, Odinak MM, Emelin AYu, Kashin AV, Gustov AV, Antipenko EA, Korshunova YuA, Davydova TA, Messler G. Vozmozhnosti preventivnoj terapii bolezni Al’cgejmera: rezul’taty 3-letnego prospektivnogo otkrytogo sravnitel’nogo issledovaniya ehffektivnosti i bezopasnosti kursovoj terapii cerebrolizinom i kavintonom u pozhilyh pacientov s sindromom myagkogo kognitivnogo snizheniya. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2010;110(1):62-69. (In Russ.)
Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm. 2001;108:459-473. https://doi.org/10.1007/s007020170067
Zhang L, Chopp M, Meier DH, Winter S, Wang L, Szalad A, Lu M, Wei M, Cui Y, Zhang ZG. Sonic Hedgehog Signaling Pathway Mediates Cerebrolysin-Improved Neurological Function After Stroke. Stroke. 2013;44:00-00. https://doi.org/10.1161/strokeaha.111.000831
Zhang Y, Chopp M, Meng Y, Zhang ZG, Doppler E, Mahmood A, Xiong Y. Improvement in functional recovery with administration of Cerebrolysin after experimental closed head injury. Journal of Neurosugery. 2014;118:1343-1355. https://doi.org/10.3171/2013.3.jns122061
Korsakova NK, Balashova EYu, Roshchina IF. EHkspress-metodika ocenki kognitivnyh funkcij pri normal’nom starenii. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2009;109:2:44-50. (In Russ.)
Korovajceva GI, Shcherbatyh TV, Selezneva ND, Gavrilova SI, Golimbet VE, Voskresenskaya NI, Rogaev EI. Geneticheskaya associaciya mezhdu allelyami gena apolipoproteina E (AROE) i razlichnymi formami bolezni Al’cgejmera. Genetika cheloveka. 2001;37(4):529-533. (In Russ.)